Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light and is used as a tool in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
IPO Year: 2018
Exchange: NYSE
Website: ramed.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2021 | $12.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. initiated coverage of Ra Medical Systems with a rating of Buy and set a new price target of $12.00
Maxim Group downgraded Ra Medical Systems from Buy to Hold
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
3 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
3 - Catheter Precision, Inc. (0001716621) (Issuer)
3 - Ra Medical Systems, Inc. (0001716621) (Issuer)
SC 13G - Catheter Precision, Inc. (0001716621) (Subject)
SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)
SC 13G - Ra Medical Systems, Inc. (0001716621) (Subject)
SC 13G/A - Ra Medical Systems, Inc. (0001716621) (Subject)
SC 13G/A - Ra Medical Systems, Inc. (0001716621) (Subject)
SC 13G/A - Ra Medical Systems, Inc. (0001716621) (Subject)
SC 13G/A - Ra Medical Systems, Inc. (0001716621) (Subject)
Name change to Catheter Precision, Inc. is effective on August 17, 2023, with trading under new ticker symbol VTAK to begin on August 18, 2023FORT MILL, SC / ACCESSWIRE / August 17, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced that its Board of Directors has approved changing the Company's corporate name to "Catheter Precision, Inc." The effective date of the name change is today, August 17, 2023. The Company has reserved the ticker symbol "VTAK" with the NYSE American, and the Company's common stock is expected to begin trading on the NYSE American under its new name and the new trading symbol effective as of the market open on August 18, 2023. The Company's new website will be unv
First patent out of six applications on file for LockeT productFORT MILL, SC / ACCESSWIRE / August 14, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced that it has received notification of allowance of the first patent to be issued for the company's LockeT product. Entitled "Vessel Closing Device", the patent to be granted is one in a family of six patent applications on file in the US, and in a number of foreign countries, including the European Community, Japan, and China.David Jenkins, interim CEO of Ra Medical Systems, commented, "We are pleased to see the first of what should be several patents to come about with the LockeT closure device. It is a clever design and invention,
Catheter Precision's VIVO System Has Been Utilized in over 1,000 ProceduresFORT MILL, SC / ACCESSWIRE / August 7, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced today that VIVO, the lead product for the electrophysiology division, has been used in more than 1000 ventricular ablation procedures. VIVO, which stands for View Into Ventricular Onset, enables physicians to learn more about patient specific anatomy and better help them plan the ablation procedure. As a result, VIVO aids in reducing overall procedure time benefitting physicians, hospitals and patients."I made a conscious decision to support a pre-commercial roll out with my own capital. I've invested well over $25mm at an ave
Name change to Catheter Precision, Inc. expected to become effective on August 17, 2023, with trading under new ticker symbol VTAK expected to begin on August 18, 2023FORT MILL, SC / ACCESSWIRE / July 31, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced that its Board of Directors has approved changing the Company's corporate name to "Catheter Precision, Inc." The effective date of the name change is expected to be August 17, 2023. The Company has reserved the ticker symbol "VTAK" with the NYSE American, and the Company's common stock is expected to begin trading on the NYSE American under its new name and the new trading symbol effective as of the market open on August 18, 2023.
New Hospitals Approve Use of VIVO and Existing Customers Increase UtilizationFORT MILL, SC / ACCESSWIRE / July 24, 2023 / Ra Medical Systems, Inc. (NYSE/American:RMED) announced today that there is an increase in clinical adoption by hospitals for its VIVO system. The three-dimensional non-invasive mapping system is one of the product lines within the company's electrophysiology division, Catheter Precision, LLC. As previously announced, Catheter Precision recently expanded its sales and clinical support team in the United States as part of its full product launch in Q2 2023.Included in the evaluations over the next few weeks are a number of hospitals including Staten Island University Hospi
Provides Evidence of Efficacy in Large Diameter Sheath Procedures, Expanding Use Beyond Electrophysiology MarketFORT MILL, SC / ACCESSWIRE / July 6, 2023 / Ra Medical Systems, Inc. (RMED:NYSE/American) today announced that its new LockeT device, used as a suture retention device for percutaneous closures, has now been utilized in structural heart procedures. The latest use was in six patients undergoing Watchman & Amulet procedures, where the left atrial appendage is closed off in patients with atrial fibrillation, and two patients receiving the AVEIR Leadless Pacemaker at HCA Trident Medical Center in North Charleston, South Carolina.HCA Trident Medical Center's Dr. Frank Cuoco, commented,
Prepares for the CE Mark and International Launch of LockeT in Third Quarter 2023FORT MILL, SC / ACCESSWIRE / July 3, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) has announced that it has undertaken a strong effort to expand its distribution outside of the US. Last week RMED announced it has filed for the CE Mark on LockeT, its new device to assist in closure of percutaneous puncture sites. The effort to expand international distribution reflects the anticipated timing of the receipt of the LockeT CE Mark, which is expected during this third quarter. Most recently, the company entered into a distribution agreement with Medilynq for distribution of RMED's products in certain countries in the
FORT MILL, SC / ACCESSWIRE / June 28, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced that its Catheter Precision subsidiary has submitted to its European Notified Body the data necessary for determination of CE marking on its LockeT product. Recently the company concluded the final step of three-year shelf-life sterility testing which clears the pathway for achievement of the CE Mark."This is yet another milestone for us," commented David Jenkins, RMED's interim CEO. "We are excited about the opportunity for LockeT, not only in the US, but also internationally. We expect to receive the CE Mark on LockeT within the third quarter of this year, and with the CE Mark available, it op
FORT MILL, SC / ACCESSWIRE / June 12, 2023 / Ra Medical Systems, Inc. (RMED:NYSE/American) announced today that its wholly owned subsidiary, Catheter Precision, Inc., has had its first customer, Heart Hospital of New Mexico at Lovelace Medical Center, complete 100 ventricular ablation procedures with the assistance of VIVO, a non-invasive 3D imaging system that identifies the earliest electrical activation of a ventricular arrhythmia."This is a significant milestone for Catheter Precision", said David Jenkins, interim CEO. "We continue to believe that physicians and hospitals will find value using VIVO and to see a hospital use it this much in a relatively short period of time demonstrates t
FORT MILL, SC / ACCESSWIRE / June 2, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced financial and company highlights for the first quarter ended March 31,2023. Among the quarter highlights are the following:RMED concluded the acquisition with the private, company Catheter Precision, Inc. ("Catheter"), in January 2023. Catheter is in the MedTech space of cardiac electrophysiology.Catheter onboarded five direct salespersons and several field clinical persons to assist in the broad US launch of its VIVO product, a product utilized to non-invasively determine the source, or earliest activation, of a ventricular arrhythmia.Catheter introduced to the market its new LockeT closure devi
FORT MILL, SC / ACCESSWIRE / June 2, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced financial and company highlights for the first quarter ended March 31,2023. Among the quarter highlights are the following:RMED concluded the acquisition with the private, company Catheter Precision, Inc. ("Catheter"), in January 2023. Catheter is in the MedTech space of cardiac electrophysiology.Catheter onboarded five direct salespersons and several field clinical persons to assist in the broad US launch of its VIVO product, a product utilized to non-invasively determine the source, or earliest activation, of a ventricular arrhythmia.Catheter introduced to the market its new LockeT closure devi
Board Committee Seeking ReplacementFORT MILL, SC / ACCESSWIRE / April 18, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced today the resignation of its CEO, Will McGuire, for personal reasons. The resignation will be effective April 28, 2023. In conjunction with his resignation as CEO, Mr. McGuire is also resigning from the RMED board of directors. The Company thanks Mr. McGuire for his service and contributions and wishes him the best in future endeavors.The RMED board of directors, as part of its governance commitment, last month established a committee for examining a transition at the CEO level. Mr. David Jenkins, the Company's Executive Chairman of the Board, will serve as Interim
FORT MILL, SC / ACCESSWIRE / March 30, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced the appointment of Steven Passey as Chief Financial Officer effective April 1, 2023, replacing Brian Conn, who has been serving as Acting Chief Financial Officer."Steven joins the executive team at a pivotal time in Ra Medical's growth", stated Ra Medical's Executive Chairman of the Board David Jenkins. "His background with publicly traded companies, budget and cost control ensures we will maintain the highest standards as a public company. In addition, he is a seasoned executive who has led M&A transactions as well as numerous equity and debt financing transactions for strategic growth. His ex
Intends to close on $8 million financingFT. MILL, SC / ACCESSWIRE / March 21, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announces that at its virtual Special Meeting of Stockholders held today, the stockholders approved all four proposals on the proxy statement filed with the Securities and Exchange Commission in February. The Company also announces that its board of directors has approved moving forward with the proposed $8 million financing as disclosed in the proxy statement. The per unit purchase price in the financing is 90% of the 5-day volume weighted average price of the Company's common stock for the period March 14, 2023 to March 20, 2023."We thank our stockholders for voting to
Ra Medical Systems (NYSE:RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. Martin Colombatto, Will McGuire and Susann L. Meline will continue to serve as directors. Joan Stafslien and Richard Mejia, Jr. have resigned as directors, with board membership remaining at five. The following adjustments have also been made to the board: Ms. Meline has been named Lead Independent Director and Chair of the Governance/Nomination Committee She will also serve on the Audit Committee. Mr. Colombatto will continue as
Catheter Precision, Inc., a medical device and technology company focused on cardiac electrophysiology, announces the appointment of Fatih Ayoglu to the newly created position of Business Development Manager—EMEA. Mr. Ayoglu will oversee clinical and sales development of Catheter Precision products in Europe, the Middle East and Africa and will report to Chief Commercial Officer Patricia Kennedy. On September 12, 2022 privately held Catheter Precision announced a definitive merger agreement with Ra Medical Systems (NYSE:RMED) ("Ra Medical Systems" or the "Company"), which, if completed, will result in a combined publicly traded company focusing on the cardiac electrophysiology market. "Fat
Ra Medical Systems, Inc. (NYSE:RMED) ("Ra Medical" or the "Company"), a medical device company focusing on developing its excimer laser system to treat vascular diseases, announces the appointment of Brian D. Conn as interim Chief Financial Officer, effective immediately. Mr. Conn will serve as the Company's Principal Financial Officer and Principal Accounting Officer. Mr. Conn has served as a consultant to Ra Medical since May 25, 2022. He replaces Will McGuire, who was appointed interim Chief Financial Officer on July 8, 2022, following the departure of Andrew Jackson, the Company's former Chief Financial Officer, on May 25, 2022. Mr. McGuire will continue in his positions as Chief Execu
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces the appointment of Susanne L. Meline to its Board of Directors, effective January 31, 2021. Her appointment expands Board membership to seven. Ms. Meline has an extensive background in finance, law and corporate governance with more than 20 years of experience advising corporate clients and their boards. In 2003, Ms. Meline co-founded investment advisor Francis Capital Management (“FCM”), where she serves as the firm’s special situations advisor. FCM is a current Ra Med
8-K - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
EFFECT - Catheter Precision, Inc. (0001716621) (Filer)
EFFECT - Catheter Precision, Inc. (0001716621) (Filer)
POS AM - Catheter Precision, Inc. (0001716621) (Filer)
POS AM - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
10-Q - Catheter Precision, Inc. (0001716621) (Filer)
FORT MILL, SC / ACCESSWIRE / February 10, 2023 / Ra Medical Systems (NYSE:RMED) today announced the date of March 21, 2023 as the date of its special shareholder meeting. Shareholders of record as of February 3, 2023 are entitled to vote at the meeting.Among other items, shareholders are requested to vote in favor of a previously announced $8 million private financing, and to vote in favor of the conversion of RMED preferred stock into common stock, the majority of which will not be converted until mid-2024, at the earliest. The preferred stock was issued in connection with the acquisition of Catheter Precision, Inc., earlier this year.About Ra Medical SystemsRa Medical, and its wholly owned
Ra Medical Systems, Inc. (NYSE:RMED) announces that it will report financial results for the three months ended March 31, 2022 after market close on Monday, May 16. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update. Pre-Registration Participants can pre-register for the conference call here: Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
Conference call begins at 4:30 p.m. Eastern time today Ra Medical Systems, Inc. (NYSE:RMED), a medical device company focusing on developing its excimer laser system to treat vascular disease, reports financial results for the three months and full year ended December 31, 2021 and provides a business update. Recent Operational Highlights Filed 510(k) application with the FDA for our next-generation DABRA catheter that incorporates a braided overjacket designed to improve robustness and includes data supporting a six-month shelf life Enrolled 13 subjects in the company's atherectomy pivotal clinical study since mid-November 2021, for a total of 98 subjects enrolled, and received approv
Ra Medical Systems, Inc. (NYSE:RMED) announces that it will report 2021 fourth quarter and full year financial results after market close on Wednesday, March 23. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update. Pre-Registration Participants can pre-register for the conference call here Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
Conference call begins at 4:30 p.m. Eastern time today Ra Medical Systems, Inc. (NYSE:RMED), a medical device company focusing on developing its excimer laser system to treat vascular disease, reports financial results for the three and nine months ended September 30, 2021 and provides a business update. Recent Operational Highlights Completed the sale of the Pharos dermatology business for net cash proceeds of $3.5 million as part of the continued focus by the company of its resources on the large peripheral artery disease (PAD) market Added two new sites and enrolled 15 additional subjects in the company's atherectomy pivotal clinical study since mid-August, for a total of 85 subjec
Ra Medical Systems, Inc. (NYSE:RMED) announces that it will report third quarter 2021 financial results after market close on Monday, November 15. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update. Pre-Registration Participants can pre-register for the conference call here: Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
Conference call begins at 4:30 p.m. Eastern time today Ra Medical Systems, Inc. (NYSE:RMED), a medical device company focusing on commercializing its excimer laser system to treat vascular disease, reports financial results for the three and six months ended June 30, 2021 and provides a business update. Recent Operational Highlights Announced the sale of the Pharos dermatology business as part of the continued focus by the company of its resources on the large peripheral artery disease (PAD) market Enrolled 20 additional subjects in the company's atherectomy pivotal clinical study since early May, for a total of 70 subjects enrolled to date in the 100-subject study Continued progres
Company focused on the large and growing peripheral artery disease (PAD) market Ra Medical Systems, Inc. (NYSE:RMED), a medical device company focused on commercializing its excimer laser system to treat vascular disease, announces the sale of its Pharos dermatology business to STRATA Skin Sciences (NASDAQ:SSKN) for $3.7 million in cash. The Pharos excimer laser is FDA-cleared for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. "We believe this transaction is in the best interest of Ra Medical and our shareholders as we intend to maximize value with a strategy that continues to focus on the large and growing PAD market," said Will McGuire, Ra Medical Systems CEO.
Ra Medical Systems, Inc. (NYSE:RMED) announces that it will report second quarter 2021 financial results after market close on Monday, August 16, 2021. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update. Pre-Registration Participants can pre-register for the conference call here: Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. L
Conference call begins at 4:30 p.m. Eastern time today Ra Medical Systems, Inc. (NYSE:RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three months ended March 31, 2021 and provides a business update. Recent Operational Highlights Enrolled 20 subjects in the company's atherectomy pivotal clinical study since mid-March for a total of 50 subjects enrolled to date Completed in-house real time aging tests that support shelf life of at least six months for next-generation DABRA catheters Continued dermatology segment revenue improvement as COVID-19 restrictions are lifted "
Name change to Catheter Precision, Inc. is effective on August 17, 2023, with trading under new ticker symbol VTAK to begin on August 18, 2023 FORT MILL, SC / ACCESSWIRE / August 17, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced that its Board of Directors has approved changing the Company's corporate name to "Catheter Precision, Inc." The effective date of the name change is today, August 17, 2023. The Company has reserved the ticker symbol "VTAK" with the NYSE American, and the Company's common stock is expected to begin trading on the NYSE American under its new name and the new trading symbol effective as of the market open on August 18, 2023. The Company's new website will be u
First patent out of six applications on file for LockeT product FORT MILL, SC / ACCESSWIRE / August 14, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced that it has received notification of allowance of the first patent to be issued for the company's LockeT product. Entitled "Vessel Closing Device", the patent to be granted is one in a family of six patent applications on file in the US, and in a number of foreign countries, including the European Community, Japan, and China. David Jenkins, interim CEO of Ra Medical Systems, commented, "We are pleased to see the first of what should be several patents to come about with the LockeT closure device. It is a clever design and invent
Catheter Precision's VIVO System Has Been Utilized in over 1,000 Procedures
Name change to Catheter Precision, Inc. expected to become effective on August 17, 2023, with trading under new ticker symbol VTAK expected to begin on August 18, 2023
Gainers Enzo Biochem (NYSE:ENZ) stock moved upwards by 12.5% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $76.0 million. Avinger (NASDAQ:AVGR) shares rose 10.1% to $0.86. The company's market cap stands at $9.1 million. NextGen Healthcare (NASDAQ:NXGN) shares increased by 8.89% to $18.0. The market value of their outstanding shares is at $1.1 billion. The company's, Q1 earnings came out today. iSpecimen (NASDAQ:ISPC) stock rose 6.87% to $1.4. The market value of their outstanding shares is at $12.6 million. Ra Medical Systems (AMEX:RMED) shares rose 6.56% to $0.72. The company's market cap stands at $4.6 million. Plus Therapeutics (N
On Monday morning, 70 companies achieved new lows for the year. Interesting Facts About Today's 52-Week Lows: Estee Lauder Cos (NYSE:EL) was the largest firm by market cap to set a new 52-week low. 9 Meters Biopharma (NASDAQ:NMTR) was the smallest firm on a market cap basis to set a new 52-week low. AppHarvest (NASDAQ:APPH) was the biggest loser, trading down 70.3% to reach its 52-week low. SWK Holdings (NASDAQ:SWKH) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low. Over the course of the first half-hour of trading on Monday, the following stocks hit new 52-week lows: Estee Lauder Cos (NYSE:EL) stock broke to
New Hospitals Approve Use of VIVO and Existing Customers Increase Utilization FORT MILL, SC / ACCESSWIRE / July 24, 2023 / Ra Medical Systems, Inc. (NYSE/American:RMED) announced today that there is an increase in clinical adoption by hospitals for its VIVO system. The three-dimensional non-invasive mapping system is one of the product lines within the company's electrophysiology division, Catheter Precision, LLC. As previously announced, Catheter Precision recently expanded its sales and clinical support team in the United States as part of its full product launch in Q2 2023. Included in the evaluations over the next few weeks are a number of hospitals including Staten Island University H
Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) stock moved upwards by 9.6% to $1.0 during Friday's after-market session. The market value of their outstanding shares is at $11.6 million. Nuwellis (NASDAQ:NUWE) shares rose 8.77% to $2.48. The market value of their outstanding shares is at $2.9 million. NanoVibronix (NASDAQ:NAOV) shares rose 8.35% to $3.5. The company's market cap stands at $5.8 million. Greenwich LifeSciences (NASDAQ:GLSI) stock rose 6.84% to $9.72. The market value of their outstanding shares is at $124.9 million. Becton, Dickinson (NYSE:BDX) shares increased by 6.63% to $282.4. Today's trading volume for this security ended up closing at 72.5K shares, which is 6.5 percen
Gainers Etao International Co (NASDAQ:ETAO) shares rose 10.3% to $0.48 during Tuesday's after-market session. The market value of their outstanding shares is at $49.1 million. Virax Biolabs Group (NASDAQ:VRAX) shares rose 8.37% to $0.44. The market value of their outstanding shares is at $7.8 million. Aprea Therapeutics (NASDAQ:APRE) stock increased by 7.14% to $3.75. The market value of their outstanding shares is at $13.9 million. Reneo Pharmaceuticals (NASDAQ:RPHM) shares moved upwards by 5.62% to $7.14. The company's market cap stands at $240.3 million. Ra Medical Systems (AMEX:RMED) shares moved upwards by 5.57% to $0.75. The company's market cap stands at $4.8 million. Mesoblast
On Monday, 65 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Pfizer (NYSE:PFE). The smallest company in terms of market cap to set a new 52-week low was Biodexa Pharmaceuticals (NASDAQ:BDRX). Tivic Health Systems (NASDAQ:TIVC) shares traded down 40.69% to reach its 52-week low, making it the biggest loser. Chijet Motor Co (NASDAQ:CJET) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low. Stocks dropping to new 52-week lows on Monday: Bristol-Myers Squibb (NYSE:BMY) shares fell to $62.30 on Monday, setting a new 52-week low with a shift of down 0.54%. Hu